BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
53 hedge funds and large institutions have $928K invested in BRAINSTORM CELL THERAPUTC in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 12 reducing their positions, and 12 closing their positions.
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
0.47% less ownership
Funds ownership: 1.18% → 0.71% (-0.47%)
9% less funds holding
Funds holding: 58 → 53 (-5)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
83% less call options, than puts
Call options by funds: $149K | Put options by funds: $888K
93% less capital invested
Capital invested by funds: $14.1M → $928K (-$13.1M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GS
GTS Securities
New York
|
+$307K |
| 2 |
LWM
Liberty Wealth Management
Oakland,
California
|
+$306K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$147K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$61K |
| 5 |
Millennium Management
New York
|
+$57.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.71M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$1.46M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$767K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$362K |
| 5 |
AHB
Abner Herrman & Brock
Jersey City,
New Jersey
|
-$204K |
BCLI Hedge Fund Activity: Q3 2023 in Review
53 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q3 2023, worth a combined $928K — down 93% from $14.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of BCLI and 8 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 15 added.
The largest buyer was GTS Securities, opening a new position worth an estimated $307K. The largest seller was Sabby Management, cutting an estimated $1.71M.
- 53 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q3 2023, down from 58 in Q2 2023.
- Funds reported $928K of BRAINSTORM CELL THERAPUTC stock for Q3 2023, down 93% quarter-over-quarter.
- 8 funds opened new BRAINSTORM CELL THERAPUTC positions in Q3 2023 and 12 closed out, a net change of -4 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q3 2023 was GTS Securities, an estimated $307K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q3 2023 was Sabby Management, an estimated $1.71M sold.
Based on aggregated 13F filings for Q3 2023.